Directors
Mr. Paul Van Damme, C.A., Corporate Governance Committee Chairman
Mr. Van Damme is currently the CFO for Bradmer Pharmaceuticals, Inc. He has served in senior financial roles for a number of public companies in both the United States and Canada. He held a number of increasingly responsible positions while at Canada Systems Group from 1983 to 1991, including a line management role, culminating in his appointment as CFO in 1988. In 1991, Mr. Van Damme joined Laidlaw Inc. and helped implement their expansion into Europe. After a period as CFO of a start-up wireless telecommunications company, he joined a private biotech company and helped raise venture financing to expand their product portfolio. In 1997, Mr. Van Damme joined Allelix Pharmaceuticals Inc. and participated in the sale of the company to NPS Pharmaceuticals, Inc. of Salt Lake City in 1999. He also served as CFO of Lorus Therapeutics Inc. and Vasogen Inc. Mr. Van Damme received a B.Comm. from the University of Toronto and an MBA from the Rotman School of Management. He is a Chartered Accountant and articled with Pricewaterhouse Coopers where he served as Audit Manager in London, England and Toronto. Mr. Van Damme currently serves as a director of the Ontario Genomics Institute.
|
